Kenneth E. Rittle

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

B. Evans, Kenneth E. Rittle, Mark G. Bock et al. · Journal of Medicinal Chemistry · 1988 · 1.4K citations · Full text

Peptide Hormone Cholecystokinin, Medicinal Chemistry, Drug Target +15

Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

B. Evans, Mark G. Bock, Kenneth E. Rittle et al. · Proceedings of the National Academy of Sciences · 1986 · 327 citations · Full text

Peptide Engineering, Peptide Science, Pharmacotherapy +19

Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260

Mark G. Bock, Robert M. DiPardo, B. Evans et al. · Journal of Medicinal Chemistry · 1989 · 309 citations · Full text

Altmetric Attention Score, Pharmacotherapy, Experimental Pharmacology +18

In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α_1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia

James C. Barrow, Philippe G. Nantermet, Harold G. Selnick et al. · Journal of Medicinal Chemistry · 2000 · 220 citations · Full text

Molecular Pharmacology, Urology, Pharmacological Study +12

Design, Synthesis, and Evaluation of a Novel 4-Aminomethyl-4-fluoropiperidine as a T-Type Ca²⁺Channel Antagonist

William D. Shipe, James C. Barrow, Zhi-Qiang Yang et al. · Journal of Medicinal Chemistry · 2008 · 131 citations · Full text

Medicinal Chemistry, Selective Antagonist, Medicine +12